off-the-shelf– tag –
-
Hopstem’s iPSC-Derived Neural Progenitor Cell hNPC01 Receives FDA IND Clearance and Fast Track Designation for Stroke and Traumatic Brain Injury
AllSci USA Overview Hopstem Biotechnology announced that its allogeneic iPSC-derived forebrain neural progenitor cell therapy, hNPC01, received both IND clearance and Fast Track designation from the U.S. FDA for treating chronic motor de... -
Advanced CAR-T/NK Therapies for Solid Tumors: iPSC-Derived CAR-NK Cells Show Promise in Efficacy and Safety
Oncodaily Global Overview In solid tumor treatment, IL-15 armed GPC3 CAR-T cells demonstrated promising early data, with cytokine release syndrome (CRS) managed by an inducible caspase-9 switch. Notably, iPSC-derived IL-15 incorporated C... -
Future of CAR T-Cell Therapy: Multi-Target, Off-the-Shelf Strategies and Manufacturing Innovation to Overcome Solid Tumors
Frontiers in Molecular Medicine Global Overview While CAR T-cell therapy revolutionized hematologic cancer treatment, challenges persist in solid tumors, including antigen heterogeneity, immunosuppressive tumor microenvironments, and poo... -
Allogene’s Off-the-Shelf CAR T Cema-Cel Secures FDA RMAT and Fast Track for High-Risk LBCL First-Line Consolidation
OncLive USA Overview Allogene Therapeutics' off-the-shelf anti-CD19 CAR T-cell therapy, cemacabtagene ansegedleucel (cema-cel), received FDA Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations for first-line consoli... -
Allogene’s Off-the-Shelf CAR T, Cema-Cel, Earns FDA RMAT and Fast Track for High-Risk LBCL First-Line Consolidation
Allogene Therapeutics, Inc. USA Overview Allogene Therapeutics has secured FDA Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations for its investigational allogeneic CAR T-cell therapy, cemacabtagene ansegedleucel (... -
iPSC-Derived Cell Therapy Pipeline Expands: Hopstem Leads Chinese Market with Neurological and Immunological Disease Applications
BioInformant USA Overview The iPSC-derived cell therapy pipeline is rapidly expanding from disease modeling to clinical applications across cardiovascular, neurological, metabolic, ocular, and oncological diseases. Hopstem Biotechnology ... -
Allogeneic CAR-T Manufacturing: Unlocking Rapid, Off-the-Shelf Cancer Therapy
Liv Hospital Turkey Overview Allogeneic CAR-T cell manufacturing is poised to revolutionize cancer treatment by providing 'off-the-shelf' solutions derived from healthy donor cells. This approach dramatically shortens treatment timelines... -
Kincell Bio Unveils Scalable Allogeneic Cell Therapy Manufacturing Platform for Large-Scale Production with Closed-System Automation
Kincell Bio USA Overview Kincell Bio has launched a scalable allogeneic cell therapy manufacturing platform designed for large-volume production, efficient cell expansion, and closed-system automation. This platform supports diverse cell... -
Wugen Rebrands as Allotera, Closes $35 Million Financing Round to Accelerate Off-the-Shelf Cell Therapy Development for Cancer and Autoimmune Diseases
Cellgenetherapyreview.com USA Overview On July 10, 2026, Wugen announced its rebranding to Allotera and the successful completion of a $35 million financing round. This rebranding and capital infusion represent a significant strategic st... -
CAR T-Cell Therapy Broadens Horizons: Expanding Indications and Manufacturing Advances Drive Wider Access Beyond Oncology to Autoimmune Diseases
AJMC USA Overview This review article comprehensively discusses how CAR T-cell therapy is entering an era of broader adoption, driven by clinical advancements, expanding indications, and enhanced manufacturing efficiency. Building on ini...
